Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
Joseph Kuo, Michael Bobardt, Udayan Chatterji, Patrick R Mayo, Daniel J Trepanier, Robert T Foster, Philippe Gallay and Daren R Ure
Journal of Pharmacology and Experimental Therapeutics August 12, 2019, jpet.119.261099; DOI: https://doi.org/10.1124/jpet.119.261099
Joseph Kuo
1 The Scripps Research Institute;
Michael Bobardt
1 The Scripps Research Institute;
Udayan Chatterji
1 The Scripps Research Institute;
Patrick R Mayo
2 Contravir Pharmaceuticals
Daniel J Trepanier
2 Contravir Pharmaceuticals
Robert T Foster
2 Contravir Pharmaceuticals
Philippe Gallay
1 The Scripps Research Institute;
Daren R Ure
2 Contravir Pharmaceuticals
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
Joseph Kuo, Michael Bobardt, Udayan Chatterji, Patrick R Mayo, Daniel J Trepanier, Robert T Foster, Philippe Gallay and Daren R Ure
Journal of Pharmacology and Experimental Therapeutics August 12, 2019, jpet.119.261099; DOI: https://doi.org/10.1124/jpet.119.261099
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
Joseph Kuo, Michael Bobardt, Udayan Chatterji, Patrick R Mayo, Daniel J Trepanier, Robert T Foster, Philippe Gallay and Daren R Ure
Journal of Pharmacology and Experimental Therapeutics August 12, 2019, jpet.119.261099; DOI: https://doi.org/10.1124/jpet.119.261099
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement